The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.
Issue link: https://lifescienceleadermag.epubxp.com/i/111709
MPI Research ��� Mattawan, MI www.mpiresearch.com ��� (269) 668-3336 key locations: Mattawan, MI contact: Ed Amat, VP of global sales ��� ed.amat@mpiresearch.com Drug Life Cycle Stages: Research & Development ��� Discovery, Preclinical Main Service Areas: Bioanalytical, Preclinical SERVICES & CAPABILITIES: General toxicology, infusion, DART, safety pharmacology, neurobehavioral sciences, anatomic/clinical pathology, DMPK, in vitro services, in vivo models, imaging, surgical services/medical device evaluations, preclinical analyses for small molecules/peptides/proteins, clinical bioanalytical analysis, immunochemistry, dose formulation/analysis, environmental/ food safety testing, antibiotic potency testing, release/stability testing, and reference standard management THERAPEUTIC AREAS: Metabolic disease, cardiovascular, orthopedic, renal, neurosciences, inflammation, infectious disease, oncology, and ophthalmology ���MPI Research is honored to be recognized as an industry leader in multiple areas. This distinction represents the voice of our sponsors and is a testament to the knowledge and experience of our scientific team. Each and every employee strives to not only meet ��� but also to exceed ��� the expectations of our sponsors as we work together in providing healthcare solutions. We are pleased that, with these awards, our sponsors recognize our commitment to them.��� ��� William U. Parfet, chairman and CEO PAREXEL International ��� Waltham, MA www.PAREXEL.com ��� (781) 487-9900 key locations: Africa, Asia Pacific, China, Europe, Middle East, South America, & U.S. info@PAREXEL.com Drug Life Cycle Stages: Research & Development ��� Discovery, Preclinical, Clinical (Phase 1, Phase 2, and Phase 3) Main Service Areas: Clinical SERVICES & CAPABILITIES: PAREXEL offers worldwide regulatory expertise, phase I-IV clinical research services, eClinical technologies that accelerate development, and integrated commercialization services. The company delivers best-practice outsourcing models focused on significant value creation. THERAPEUTIC AREAS: PAREXEL has expertise across a broad range of therapeutic areas including oncology, cardiology, neurology, metabolism/endocrine, and infectious disease. KEY INDUSTRY PARTNERS: PAREXEL serves the top 50 pharmaceutical companies, the top 10 global biotech companies, as well as hundreds of small and medium-sized biopharma companies. The company has also publicly announced strategic partnerships with BMS, GSK, Lilly, Merck, and Pfizer. ���Over the past 30 years, PAREXEL has been focused on delivering safe and effective treatments to patients worldwide, through the implementation and refinement of clinical development expertise and leading-edge technology. As one of the first clinical research organizations, we have evolved into a provider of a broad range of services for biopharmaceutical companies of all sizes ��� including integrated clinical development, regulatory affairs consulting, commercialization services, and technologies that expedite time-to-market.��� ��� Josef von Rickenbach, chairman and CEO PPD ��� Wilmington, NC ��� www.ppdi.com ��� (910) 251-0081 key locations: Austin, TX; Beijing, China; Bells Hill, Scotland; Cambridge, United Kingdom; Madison, WI; Research Triangle Park, NC; Richmond, VA; and Wilmington, NC. ppdinfo@ppdi.com Drug Life Cycle Stages: Research & Development ��� Discovery, Preclinical, Clinical (Phase 1, Phase 2, and Phase 3) Main Service Areas: Bioanalytical, Clinical, Preclinical SERVICES & CAPABILITIES: Pre-Clinical and Early Development Services ��� BioDuro, A PPD�� Company, X-Chem; MAB Discovery, Phase I clinic, CMC consulting, pharmacology/toxicology. Clinical Development Services ��� Full service phase II-IIIb clinical studies, project management, clinical trial monitoring, data management, biostatistics, pharmacovigilance, feasibility studies, therapeutic expertise, biosimilars, adaptive trial design, patient recruitment, regulatory affairs, quality and compliance, IVR/IWR system services, late stage research, registries and observational studies, epidemiology and health outcomes, risk management and REMS, clinical supplies. Laboratory Services ��� Phase I-IV global central labs, bioanalytical labs, cGMP labs, vaccines and biologics THERAPEUTIC AREAS: Cardiovascular, central nervous system, critical care, dental pain research, dermatology, endocrine and metabolic, gastroenterology, hematology and oncology, immunology, infectious diseases, ophthalmology, pediatrics, respiratory, and urology KEY INDUSTRY PARTNERS: PPD has worked with all of the top 50 pharmaceutical companies* and 600+ biotechnology companies (*Ranked according to R&D; spend). ���As an industry leader, PPD is committed to excellence, quality, and exceptional service delivery. Innovative technologies, processes, and solutions allow us to work smarter and more efficiently for our valued clients. Strong relationships are built on the successful delivery of projects. Ultimately, however, the greatest contributor to success is our people. It is an honor to be recognized for the efforts PPD employees make to help bring new and improved therapies to patients in need.��� ��� David Simmons, chairman and CEO The CRO Leadership Awards 2013 27